Cargando…

Circulating tumor DNA as a therapy response marker in metastatic colorectal cancer

Detalles Bibliográficos
Autores principales:	Ma, Xiaoju Max, Yaung, Stephanie J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2022
Materias:	Research Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232209/ https://www.ncbi.nlm.nih.gov/pubmed/35769518 http://dx.doi.org/10.18632/oncoscience.559

Ejemplares similares

Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA
por: Yaung, Stephanie J., et al.
Publicado: (2022)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

Electrochemical Biosensors for Circulating Tumor DNA Detection
por: Wang, Ke, et al.
Publicado: (2022)

Evaluation of circulating tumor DNA as a biomarker for gynecological tumors
por: Liu, Kang-Sheng, et al.
Publicado: (2020)

Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy
por: Yang, Wentao, et al.
Publicado: (2022)

Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response
por: Jia, Ning, et al.
Publicado: (2019)

Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection
por: Pantel, Klaus
Publicado: (2016)

Circulating tumor cells and neutrophil-lymphocyte ratio are predictive markers for metastatic colorectal cancer patients
por: Li, Heming, et al.
Publicado: (2021)

Corrigendum: Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy
por: Yang, Wentao, et al.
Publicado: (2022)

Circulating tumor DNA applications in monitoring the treatment of metastatic colorectal cancer patients
por: Kazemifard, Nesa, et al.
Publicado: (2019)

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer
por: Lee, Dae-Won, et al.
Publicado: (2023)

Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
por: Patelli, Giorgio, et al.
Publicado: (2021)

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer
por: Heidrich, Isabel, et al.
Publicado: (2021)

Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer
por: Thomsen, Caroline B., et al.
Publicado: (2020)

Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer
por: Yaung, Stephanie J., et al.
Publicado: (2022)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
por: Agashe, Ruchi, et al.
Publicado: (2020)

Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2019)

Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer
por: Gong, Jun, et al.
Publicado: (2022)

RAS testing in metastatic colorectal cancer: advances in Europe
por: Van Krieken, J Han JM, et al.
Publicado: (2015)

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
por: Boonstra, Pieter A., et al.
Publicado: (2020)

Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma
por: von Felden, Johann, et al.
Publicado: (2018)

Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers
por: Yang, Xin, et al.
Publicado: (2022)

Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA
por: Benešová, Lucie, et al.
Publicado: (2019)

Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2021)

Small EVs-Associated DNA as Complementary Biomarker to Circulating Tumor DNA in Plasma of Metastatic Colorectal Cancer Patients
por: Galbiati, Silvia, et al.
Publicado: (2021)

Molecular markers in circulating tumour cells from metastatic colorectal cancer patients
por: Gazzaniga, Paola, et al.
Publicado: (2010)

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer
por: Topham, James T., et al.
Publicado: (2023)

Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Sex disparities in DNA damage response pathways: Novel determinants in cancer formation and therapy
por: Cardano, Miriana, et al.
Publicado: (2022)

Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer
por: Chen, Gong, et al.
Publicado: (2021)

Circulating tumor DNA methylation marker MYO1-G for diagnosis and monitoring of colorectal cancer
por: Lin, Wu-Hao, et al.
Publicado: (2021)

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
por: Yao, Jiannan, et al.
Publicado: (2018)

Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer
por: Shi, Min, et al.
Publicado: (2022)

Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
por: Radosevich, James A, et al.
Publicado: (2019)

Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer
por: Takayama, Yuji, et al.
Publicado: (2018)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

Clinical Characteristics of Metastatic Colorectal Cancer Combined with Gastrointestinal Perforation and Prognostic Value of Circulating Tumor DNA
por: Yang, Hong, et al.
Publicado: (2022)

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2022)

NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
por: Raunkilde, Louise, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mish8ku93uak2u8bug49hcck0e